EA200401340A1 - Фармацевтическая комбинация для лечения доброкачественной гиперплазии простаты или для долговременной профилактики острой ишурии - Google Patents

Фармацевтическая комбинация для лечения доброкачественной гиперплазии простаты или для долговременной профилактики острой ишурии

Info

Publication number
EA200401340A1
EA200401340A1 EA200401340A EA200401340A EA200401340A1 EA 200401340 A1 EA200401340 A1 EA 200401340A1 EA 200401340 A EA200401340 A EA 200401340A EA 200401340 A EA200401340 A EA 200401340A EA 200401340 A1 EA200401340 A1 EA 200401340A1
Authority
EA
Eurasian Patent Office
Prior art keywords
long
acute
hyperplasia
pharmaceutical combination
ischuria
Prior art date
Application number
EA200401340A
Other languages
English (en)
Other versions
EA008377B1 (ru
Inventor
Вольфганг Байкер
Людвиг Мельбургер
Original Assignee
Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29271571&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200401340(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE2002118392 external-priority patent/DE10218392A1/de
Priority claimed from DE2002118611 external-priority patent/DE10218611A1/de
Application filed by Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг filed Critical Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг
Publication of EA200401340A1 publication Critical patent/EA200401340A1/ru
Publication of EA008377B1 publication Critical patent/EA008377B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

В заявке описана новая фармацевтическая комбинация для лечения доброкачественной гиперплазии простаты (ДГП) или для долговременной профилактики острой ишурии (ОИ).Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200401340A 2002-04-24 2003-04-17 Фармацевтическая комбинация для лечения доброкачественной гиперплазии простаты или для долговременной профилактики острой ишурии EA008377B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE2002118392 DE10218392A1 (de) 2002-04-24 2002-04-24 Verwendung von Arzneimittelkombinationen zur Behandlung von benigner Prostatahyperplasie
DE2002118611 DE10218611A1 (de) 2002-04-25 2002-04-25 Verwendung einer Tamsulosin enthaltenden Arzneimittelkombination zur Behandlung von benigner Prostatahyperplasie
PCT/EP2003/004034 WO2003090753A1 (en) 2002-04-24 2003-04-17 Pharmaceutical combination for the treatment of benign prostatic hyperplasia or for the long-term prevention of acute urinary retention

Publications (2)

Publication Number Publication Date
EA200401340A1 true EA200401340A1 (ru) 2005-06-30
EA008377B1 EA008377B1 (ru) 2007-04-27

Family

ID=29271571

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200401340A EA008377B1 (ru) 2002-04-24 2003-04-17 Фармацевтическая комбинация для лечения доброкачественной гиперплазии простаты или для долговременной профилактики острой ишурии

Country Status (22)

Country Link
US (2) US20030225118A1 (ru)
EP (2) EP1743656A3 (ru)
JP (1) JP2005524693A (ru)
CN (1) CN1646135A (ru)
AT (1) ATE361075T1 (ru)
AU (1) AU2003227643A1 (ru)
BR (1) BR0309435A (ru)
CA (1) CA2479992A1 (ru)
CY (1) CY1107674T1 (ru)
DE (1) DE60313603T2 (ru)
DK (1) DK1501517T3 (ru)
EA (1) EA008377B1 (ru)
ES (1) ES2287474T3 (ru)
HR (1) HRP20040994A2 (ru)
IL (1) IL163976A0 (ru)
MX (1) MXPA04010408A (ru)
NO (1) NO20044333L (ru)
NZ (1) NZ536514A (ru)
PL (1) PL371430A1 (ru)
PT (1) PT1501517E (ru)
RS (1) RS92304A (ru)
WO (1) WO2003090753A1 (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04010408A (es) * 2002-04-24 2005-02-17 Boehringer Ingelheim Pharma Combinacion farmaceutica para el tratamiento de hiperplasia prostatica benigna o para la prevencion a largo plazo de la retencion urinaria aguda.
RU2006119331A (ru) * 2003-11-03 2007-12-27 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ АГОНИСТ β3-АДРЕНОРЕЦЕПТОРА, α-АНТАГОНИСТ И/ИЛИ ИНГИБИТОР 5α-РЕДУКТАЗЫ
CN101452893B (zh) * 2003-11-14 2011-04-13 株式会社半导体能源研究所 显示装置及其制造法
WO2006055659A2 (en) * 2004-11-15 2006-05-26 Smithkline Beecham Corporation Fixed dose combination op dutasteride and tamsulosin
CN102309495A (zh) * 2010-06-30 2012-01-11 北京润德康医药技术有限公司 一种复方制剂及其制备方法
WO2012110092A1 (en) 2011-02-17 2012-08-23 Synthon Bv Tamsulosin derivatives
BRPI1103204A2 (pt) * 2011-06-03 2014-02-25 Eurofarma Lab S A Composição farmacêutica para o tratamento de hiperplasia prostática benigna
WO2013123965A1 (en) 2012-02-20 2013-08-29 Synthon Bv A fixed dose pharmaceutical formulation
US10596127B2 (en) 2013-03-14 2020-03-24 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
BR102013020508B1 (pt) * 2013-08-12 2021-01-12 Ems S/A. Forma de dosagem que compreende um inibidor de esteroide 5-alfa-redutase e um bloqueador alfa, processo para a preparaçãode uma forma de dosagem e uso da forma de dosagem
EP2949319A1 (en) 2014-05-26 2015-12-02 Galenicum Health S.L. Pharmaceutical compositions comprising an active agent
EP3355877A4 (en) * 2015-09-30 2019-05-15 Wellesley Pharmaceuticals, LLC COMPOSITION FOR REDUCING URINATION FREQUENCY, METHOD FOR THE PREPARATION AND USE THEREOF
US10172910B2 (en) * 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
CN115969860A (zh) * 2021-10-14 2023-04-18 上海汇伦医药股份有限公司 一种药物组合物及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391825A (en) * 1980-02-08 1995-02-21 Yamanouchi Pharmaceutical Co., Ltd. Sulfamoyl substituted phenethylamine intermediates
JPS56110665A (en) 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Sulfamoyl-substituted phenetylamine derivative and its preparation
NZ211145A (en) 1984-02-27 1988-10-28 Merck & Co Inc 4-aza-5-alpha-androst-1-en-3-ones and pharmaceutical compositions
US4760071A (en) 1984-02-27 1988-07-26 Merck & Co., Inc. 17β-N-monosubstituted carbamoyl-4-aza-5α-androst-1-en-3-ones which are active as testosterone 5α-reductase inhibitors
US4772475A (en) 1985-03-08 1988-09-20 Yamanouchi Pharmaceutical Co., Ltd. Controlled-release multiple units pharmaceutical formulation
DE3888994T2 (de) 1987-04-03 1994-11-03 Merck & Co Inc Behandlung von androgener Alopecia mit 17-beta-n-mono-substituierten-carbamoyl-4-aza-5-alpha-androst-1-en-3-onen.
EP0285383B1 (en) 1987-04-03 1994-03-16 Merck & Co. Inc. Treatment of prostatic carcinoma with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones
IL101243A (en) * 1991-03-20 1999-12-22 Merck & Co Inc Pharmaceutical preparations for the treatment of benign prostatic hyperplasia containing steroid history
TW369521B (en) * 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
TW382595B (en) 1993-10-15 2000-02-21 Merck & Co Inc Pharmaceutical composition for use in arresting and reversing androgenic alopecia
US6423719B1 (en) * 1999-02-16 2002-07-23 Upsher-Smith Laboratories, Inc. Method for treating benign prostate hyperplasia
AU7703700A (en) * 1999-09-22 2001-04-24 Merck & Co., Inc. Treatment of lower urinary tract symptoms and pharmaceutical compositions for use therein
MXPA04010408A (es) * 2002-04-24 2005-02-17 Boehringer Ingelheim Pharma Combinacion farmaceutica para el tratamiento de hiperplasia prostatica benigna o para la prevencion a largo plazo de la retencion urinaria aguda.

Also Published As

Publication number Publication date
DK1501517T3 (da) 2007-06-11
CA2479992A1 (en) 2003-11-06
EP1501517B1 (en) 2007-05-02
PT1501517E (pt) 2007-05-31
EP1501517A1 (en) 2005-02-02
US20030225118A1 (en) 2003-12-04
IL163976A0 (en) 2005-12-18
JP2005524693A (ja) 2005-08-18
PL371430A1 (en) 2005-06-13
NO20044333L (no) 2004-11-09
AU2003227643A1 (en) 2003-11-10
DE60313603D1 (de) 2007-06-14
CY1107674T1 (el) 2013-04-18
ES2287474T3 (es) 2007-12-16
ATE361075T1 (de) 2007-05-15
BR0309435A (pt) 2005-02-15
WO2003090753A8 (en) 2004-11-04
EP1743656A2 (en) 2007-01-17
HRP20040994A2 (en) 2005-02-28
EA008377B1 (ru) 2007-04-27
DE60313603T2 (de) 2008-01-03
RS92304A (en) 2006-10-27
EP1743656A3 (en) 2007-03-07
WO2003090753A1 (en) 2003-11-06
CN1646135A (zh) 2005-07-27
MXPA04010408A (es) 2005-02-17
NZ536514A (en) 2006-11-30
US20070197666A1 (en) 2007-08-23

Similar Documents

Publication Publication Date Title
CY1107674T1 (el) Φαρμακευτικος συνδυασμος για τη θεραπευτικη αντιμετωπιση της καλοηθους υπερπλασιας του προστατη ή για την μακροπροθεσμη προληψη της οξειας επισχεσης ουρων
DE60023982D1 (de) System zur Behandlung von benigner Prostatahyperplasie
IL169685A0 (en) Treatment of benign prostatic hyperplasia using energolytic agents
EP1961418A4 (en) USE OF ISOTHIOCYANATE-BASED COMPOUNDS IN THE TREATMENT OF PROSTATIC DISEASES AND SKIN CANCER
NZ517616A (en) Use of retigabin for treating neuropathic pain
DK1373215T3 (da) Gelanamycinderivater egnet til behandling af cancer
DE60025632D1 (de) Thrombopoietin-mimetika
DK0968208T3 (da) Quinolin- og quinazolin-forbindelser som er nyttige i terapi især til behandling af godartet prostatisk hyperplasia
NO20034166L (no) Molekyl¶re konjugater for anvendelse ved behandling av cancer
BR0206639A (pt) Combinações de inibidor(es) da absorção do esterol com modificador(es) do sangue para o tratamento de condições vasculares
ATE362374T1 (de) Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust
AU3011299A (en) Combination therapy for the treatment of benign prostatic hyperplasia
DK0565296T3 (da) Anvendelse af melatonin til fremstilling af et lægemiddel til behandling af godartet prostatahyperplasi
DK1534388T3 (da) Bruseanordning
PA8453601A1 (es) Inhibidores de la farnesil transferasa combinados con inhibidores de la hmg coa reductasa para tratamiento del cancer
HN2002000197A (es) Proceso para la produccion de quinazolinas
DK1438034T3 (da) Anvendelse af -phenyl-3-dimethylaminiopropanforbindelser til behandling af urininkontinens
ATE250580T1 (de) Substituierte pyridino-arylpiperazine zur behandlung benigner prostatahyperplasie
EA200401100A1 (ru) 1α-ФТОР-25-ГИДРОКСИ-16,23E-ДИЕН-26,27-БИСГОМО-20-ЭПИХОЛЕКАЛЬЦИФЕРОЛ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ
GB0301016D0 (en) Treatment of benign prostatic hyperplasia
EP1300159A4 (en) REMEDIES FOR CANCER
SI1501517T1 (sl) Farmacevtska kombinacija za zdravljenje benigne hiperplazije prostate ali za dolgotrajno preprečevanje akutne retencije urina
EP1485117A4 (en) METHOD FOR THERAPEUTIC TREATMENT OF BENIGN PROSTATE HYPERTROPHY (BPH)
ECSP982362A (es) Compuestos de quinolina y quinazolina utiles en terapia
MY140504A (en) Statin-mmp inhibitor combinations

Legal Events

Date Code Title Description
MC4A Revocation of a eurasian patent under opposition procedure